Ignite Creation Date:
2025-12-24 @ 11:18 PM
Ignite Modification Date:
2025-12-25 @ 8:57 PM
Study NCT ID:
NCT04375956
Status:
UNKNOWN
Last Update Posted:
2021-12-20
First Post:
2020-04-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients
Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-26
Start Date Type:
ACTUAL
Primary Completion Date:
2025-06-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-06-15
Completion Date Type:
ESTIMATED
First Submit Date:
2020-04-13
First Submit QC Date:
None
Study First Post Date:
2020-05-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-12-06
Last Update Post Date:
2021-12-20
Last Update Post Date Type:
ACTUAL